Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and acceptability of deferiprone delayed release tablets in systemic iron overload
2018-004016-22Phase 2Completed
- Sponsor
- ApoPharma Inc.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of deferiprone in hereditary hemochromatosis (HH) and iron overload (2 arms), sponsored by ApoPharma Inc. Primary endpoint: Incidence of liver enzyme elevations meeting safety concern criteria. Started Dec 2018; status: completed.
02
Drugs
deferiprone
03
Conditions
hereditary hemochromatosis (HH)iron overload
Beyond the preview
Go deeper on 2018-004016-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004016-22.